Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Potrasertib · IMP7068

Small molecule · Inhibitor of WEE1 · developed by Impact Therapeutics

Phase 1 Most advanced trial (none active)

IBO Developer

1 Registered trials

What is Potrasertib?

Potrasertib is an orally bioavailable small-molecule inhibitor of the tyrosine kinase WEE1. It inhibits WEE1-mediated phosphorylation of CDK1, promoting premature mitosis and mitotic arrest that leads to accumulation of unrepaired DNA damage and apoptosis in p53-deficient tumor cells. It is being studied in advanced solid tumors.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: IMP7068
Drug type: Small molecule
Targets: WEE1
Mechanism: Inhibitor of WEE1
Pathways: G2-M checkpoint, cell cycle arrest, apoptosis
Therapy area: Oncology
Developer: Impact Therapeutics, Inc. (IBO)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1
UNII: 621K13UG4B

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT04768868	Phase 1	Advanced Solid Tumors	Unknown	IBO

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Advanced Solid Tumors

Other drugs acting on WEE1

ACR-2316 Phase 1/2 Adavosertib Phase 2 APR-1051 Phase 1

More from Impact Therapeutics

IMP4927 Investigational IMP9064 Investigational Senaparib Investigational

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the IBO page.

Follow IBO, the company behind Potrasertib

See IBO's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

IBO catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z